Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Quality Assurance: SOP for Managing Deviations in Quality Assurance Processes – V 2.0

Posted on By

Quality Assurance: SOP for Managing Deviations in Quality Assurance Processes – V 2.0

Standard Operating Procedure for Managing Deviations in Quality Assurance Processes


Department Quality Assurance
SOP No. SOP/QA/184/2025
Supersedes SOP/QA/184/2022
Page No. Page 1 of 15
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

To define a systematic approach for identifying, documenting, evaluating, investigating, and resolving deviations in quality assurance (QA) processes associated with sterile injectable manufacturing. This ensures consistent compliance with GMP, WHO, and ICH guidelines and maintains product integrity.

2.

Scope

This SOP is applicable to all deviations—planned or unplanned—that occur within QA operations, including batch record reviews, validation activities, document control, internal audits, and QA checks in sterile manufacturing.

3. Responsibilities

  • QA Officer: Identifies and reports deviations, initiates deviation forms, and assists in investigation.
  • Department Head: Participates in root cause analysis and proposes CAPA actions.
  • Investigation Team: Conducts detailed deviation assessments and RCA.
  • QA Manager: Reviews, approves, and tracks the deviation records until closure.

4. Accountability

The Head of Quality Assurance is accountable for ensuring that all deviations are addressed and documented according to this SOP, and that corrective and preventive actions (CAPA) are implemented effectively.

5. Procedure

5.1 Deviation Classification

  1. Planned Deviation: A pre-authorized deviation from an SOP or process, approved in advance for justified reasons (e.g., equipment replacement).
  2. Unplanned Deviation: An unanticipated event or variance from standard procedures (e.g., environmental deviation, human error, documentation error).

5.2 Initiation of Deviation

  1. Any staff member identifying a deviation must immediately inform the QA Officer.
  2. QA Officer fills the Deviation Form (Annexure-1), assigns a unique deviation ID, and notifies the QA Manager.
  3. Deviation is logged into the Deviation Register (Annexure-2).

5.3 Investigation Process

  1. The QA Manager forms an investigation team including representatives from relevant departments (production, QC, maintenance, etc.).
  2. Conduct Root Cause Analysis (RCA) using tools like:
    • 5 Whys Analysis
    • Ishikawa (Fishbone) Diagram
    • Brainstorming sessions
  3. Document findings and potential root causes in the deviation report.

5.4 Risk Assessment

  1. Assess the impact of deviation on product quality, patient safety, and regulatory compliance.
  2. Risk is categorized as:
    • Critical – significant risk to product quality/safety
    • Major – moderate risk, may require rework/reprocessing
    • Minor – low/no impact, procedural issue

5.5 Corrective and Preventive Action (CAPA)

  1. Propose CAPA based on the investigation outcome.
  2. Assign responsibility and timeline for implementation.
  3. QA monitors CAPA effectiveness and documents completion status (Annexure-3).

5.6 Review and Approval

  1. QA Manager reviews the complete deviation report including investigation findings, risk assessment, and CAPA.
  2. After satisfactory review, the deviation is marked as Closed.

5.7 Trend Analysis

  1. QA shall conduct quarterly trend analysis on all deviations to identify patterns or systemic issues.
  2. Findings are used for continual improvement and training programs.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action
  • RCA: Root Cause Analysis
  • GMP: Good Manufacturing Practice

7. Documents

  1. Deviation Form – Annexure-1
  2. Deviation Register – Annexure-2
  3. CAPA Implementation Record – Annexure-3

8. References

  • WHO Technical Report Series No. 986 Annex 2 – GMP
  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211 – Subpart F: Production and Process Controls

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation QA Executive QA Manager Head QA
Department Quality Assurance Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Deviation Form

Deviation ID DEV-QA-0175
Date 21/06/2025
Reported By Sunita Reddy
Description Missing signature on final batch record page
Type Unplanned

Annexure-2: Deviation Register

Deviation ID Date Type Status
DEV-QA-0175 21/06/2025 Unplanned Closed

Annexure-3: CAPA Implementation Record

CAPA No. CAPA-QA-0192
Description Training on documentation completeness conducted
Responsible Rajesh Kumar
Implementation Date 23/06/2025
Status Implemented

Revision History:

Revision Date Revision No. Details Reason Approved By
01/06/2022 1.0 Initial SOP Release New SOP Head QA
24/06/2025 2.0 Added RCA tools and risk assessment classification Annual Review Head QA
See also  In-Process Control: SOP for Real-Time Monitoring of Vial Fill Levels - V 2.0
Injectables V 2.0 Tags:Aseptic processing SOP, Aseptic technique in sterile manufacturing, Cleanroom SOP for injectables, SOP for ampoule sealing, SOP for autoclave sterilization, SOP for container closure integrity testing, SOP for environmental monitoring in aseptic area, SOP for gowning in cleanroom, SOP for in-process checks in sterile manufacturing, SOP for injectable formulation, SOP for lyophilizer operation, SOP for sterile filtration, SOP for sterilization validation, SOP for vial filling, SOP for visual inspection of injectables, Sterile area cleaning SOP, Sterile filling line SOP, Sterile injectable quality control SOP, Sterile injection SOP, Sterile manufacturing procedure

Post navigation

Previous Post: Certification and Qualification After SOP Training
Next Post: Elixir Department: SOP for UV Sterilization of Clean Equipment – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version